CN107208107A8 - 伤口愈合的方法 - Google Patents

伤口愈合的方法 Download PDF

Info

Publication number
CN107208107A8
CN107208107A8 CN201580070791.8A CN201580070791A CN107208107A8 CN 107208107 A8 CN107208107 A8 CN 107208107A8 CN 201580070791 A CN201580070791 A CN 201580070791A CN 107208107 A8 CN107208107 A8 CN 107208107A8
Authority
CN
China
Prior art keywords
lactic acid
wound healing
protein
acid bacteria
plasmid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201580070791.8A
Other languages
English (en)
Other versions
CN107208107B (zh
CN107208107A (zh
Inventor
埃维利纳·威格斯乔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ilya Pharma AB
Original Assignee
Ilya Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ilya Pharma AB filed Critical Ilya Pharma AB
Priority to CN202110680754.6A priority Critical patent/CN113403244B/zh
Publication of CN107208107A publication Critical patent/CN107208107A/zh
Publication of CN107208107A8 publication Critical patent/CN107208107A8/zh
Application granted granted Critical
Publication of CN107208107B publication Critical patent/CN107208107B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明涉及当被转化进入乳酸细菌细胞时能够表达靶向免疫细胞的蛋白质的质粒，其中所述蛋白质选自由鼠和人CXCL12 1α；CXCL17和Ym1组成的组。本发明还涉及利用所述质粒转化的乳酸细菌，以及所述乳酸细菌用于人和动物伤口愈合的用途。
CN201580070791.8A 2014-12-23 2015-12-23 伤口愈合的方法 Active CN107208107B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110680754.6A CN113403244B (zh) 2014-12-23 2015-12-23 伤口愈合的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1451658-7 2014-12-23
SE1451658 2014-12-23
PCT/EP2015/081146 WO2016102660A1 (en) 2014-12-23 2015-12-23 Methods for wound healing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110680754.6A Division CN113403244B (zh) 2014-12-23 2015-12-23 伤口愈合的方法

Publications (3)

Publication Number Publication Date
CN107208107A CN107208107A (zh) 2017-09-26
CN107208107A8 true CN107208107A8 (zh) 2017-12-26
CN107208107B CN107208107B (zh) 2021-07-09

Family

ID=55080095

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580070791.8A Active CN107208107B (zh) 2014-12-23 2015-12-23 伤口愈合的方法
CN202110680754.6A Active CN113403244B (zh) 2014-12-23 2015-12-23 伤口愈合的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110680754.6A Active CN113403244B (zh) 2014-12-23 2015-12-23 伤口愈合的方法

Country Status (9)

Country Link
US (3) US10696974B2 (zh)
EP (2) EP3237622B1 (zh)
JP (2) JP6581208B2 (zh)
KR (2) KR102081493B1 (zh)
CN (2) CN107208107B (zh)
AU (2) AU2015370982B2 (zh)
CA (1) CA2971520C (zh)
ES (1) ES2864373T3 (zh)
WO (1) WO2016102660A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017132202A1 (en) 2016-01-25 2017-08-03 Nant Holdings Ip, Llc Nk cells with altered cxcl12/cxcr4 signaling
US20190300843A1 (en) * 2016-10-31 2019-10-03 Kimberly-Clark Worldwide, Inc. Method for archiving a microbiome
CN110157733A (zh) * 2018-02-11 2019-08-23 四川大学 重组mIL-22BP载体、脂质体复合物及其制备方法和用途
IL305597B1 (en) * 2018-07-24 2024-04-01 Biogaia Ab Selection and use of melatonin-promoting bacteria to reduce infantile colic
EP3827102A1 (en) * 2018-07-24 2021-06-02 Biogaia AB Therapeutic methods using bacterial strains which are capable of increasing adenosine levels
CN109112155A (zh) * 2018-08-02 2019-01-01 南昌大学 乳酸乳球菌mg1363的构建及其在治疗细菌性阴道炎中的应用
CN109234298A (zh) * 2018-10-30 2019-01-18 南昌大学 一种卷曲乳杆菌atcc55221的构建及其在治疗产妇乳头皲裂中的应用
CN109517772A (zh) * 2018-10-30 2019-03-26 南昌大学 一种乳酸乳球菌mg1363的构建及其在治疗产妇乳头皲裂中的应用
JP7045671B2 (ja) 2018-11-12 2022-04-01 有限会社バイオ研 皮膚塗布用の皮膚創傷治癒促進組成物、その製造方法、及び創傷被覆材
BR112021023682A2 (pt) * 2019-06-24 2022-04-12 Mendes Srl Composição com ação antibacteriana e de reepitelização incluindo probióticos
CN110623792B (zh) * 2019-09-23 2022-05-06 温州医科大学附属第一医院 一种医学敷料及其制备方法
CN114470007A (zh) * 2020-11-13 2022-05-13 葡萄王生技股份有限公司 含乳酸菌发酵产物之创伤外用组合物及其用途
WO2023063314A1 (ja) 2021-10-11 2023-04-20 味の素株式会社 異種Ｔａｔ系タンパク質を発現するよう改変された細菌
WO2023118327A1 (en) 2021-12-22 2023-06-29 Ilya Pharma Ab Live bacteria as excipients for proteins
WO2023126446A1 (en) 2021-12-29 2023-07-06 Ilya Pharma Ab Treatment of therapy-induced enteropathy

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9521568D0 (en) 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
AU734252B2 (en) * 1997-02-07 2001-06-07 Shionogi & Co., Ltd. Novel mouse CXC chemokine receptor
DE60031405T2 (de) 1999-07-05 2007-08-16 Actogenix Nv Bereitstellung von peptiden mit kleeblattstruktur
CA2311201A1 (en) 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
WO2006124013A2 (en) * 2004-04-30 2006-11-23 Five Prime Therapeutics, Inc. Novel stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof, and method of use
EP1789529B1 (en) 2004-08-20 2013-10-02 Actogenix N.V. Method to improve lactococcus preservation
ES2626610T3 (es) 2005-08-30 2017-07-25 Intrexon Actobiotics Nv Bacterias de ácido láctico productoras del anti-TNF alfa para el tratamiento de la enfermedad inflamatoria intestinal
CA2621468A1 (en) 2005-10-03 2007-04-12 Actogenix Nv Use of recombinant yeast strain producing an anti-inflammatory compound in the manufacture of a medicament to treat colitis
US8748126B2 (en) 2005-11-29 2014-06-10 Actogenix N.V. Induction of mucosal tolerance to antigens
US8852916B2 (en) 2010-01-22 2014-10-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with microorganisms
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
WO2007128757A2 (en) 2006-05-02 2007-11-15 Actogenix N.V. Microbial intestinal delivery of obesity related peptides
WO2008071751A1 (en) 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
WO2008074331A1 (en) 2006-12-19 2008-06-26 Ferrosan A/S Wound or tissue dressing comprising lactic acid bacteria
RU2009127718A (ru) 2006-12-19 2011-01-27 Ферросан А/С (Dk) Раневой или тканевой перевязочный материал, содержащий молочнокислые бактерии
AU2008204442B2 (en) 2007-01-12 2013-03-14 Intrexon Actobiotics Nv Lactococcus promoters and uses thereof
BRPI0807857A2 (pt) 2007-01-25 2014-05-27 Actogenix Nv Tratamento de doença imune por meio de distribuição através da mucosa de antígenos.
WO2008096359A2 (en) * 2007-02-08 2008-08-14 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of multiple sclerosis and methods of using same
EP2164512A2 (en) 2007-06-20 2010-03-24 Actogenix N.V. Methods and compositions for treating mucositis
WO2009060608A1 (ja) 2007-11-07 2009-05-14 Ono Pharmaceutical Co., Ltd. Ｓｄｆ－１を含有してなる徐放性組成物
CA2709398C (en) 2007-12-14 2017-11-07 The Cleveland Clinic Foundation Use of stromal cell-derived factor 1 for promoting wound healing
US8367109B2 (en) 2008-04-09 2013-02-05 Brookhaven Science Associates, Llc Microbes encapsulated within crosslinkable polymers
DK3181682T3 (da) 2008-09-29 2021-07-05 Intrexon Actobiotics Nv Reduceret kolonisering af mikrober på slimhinden
US20100143305A1 (en) * 2008-12-08 2010-06-10 James Allen Lemke Treatment of hiv and aids using probiotic lactobacillus reuteri
JP2012524781A (ja) * 2009-04-21 2012-10-18 ユニバーシティー・オブ・マイアミ 虚血性及び糖尿病性創傷の治癒を促進する組成物、キット及び方法
EP2243487A1 (en) 2009-04-23 2010-10-27 Actogenix N.V. Enteric coated formulation
CN102414310B (zh) 2009-04-30 2015-05-06 阿克图杰尼斯公司 用于冷冻干燥乳酸菌的冷冻保护剂
CN102459571B (zh) * 2009-06-04 2014-01-08 香港中文大学 抗炎细菌
CL2009001506A1 (es) 2009-07-01 2009-09-25 Univ Concepcion Parche o aposito a base de hidrocoloides compuesto por una lamina de gelatina reticulada que comprende cepas viables probioticas productoras de acido lactico de lactobacillus acidophilus dsm 17371, un agente reticulante y un agente plastificante; y proceso para elaborar dicho parche.
EP2473196B1 (en) 2009-08-28 2017-05-31 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
US20120183503A1 (en) 2009-09-29 2012-07-19 Actogenix N.V. Lactobacillus and streptococcus promoters and uses thereof
GB2482536B (en) * 2010-08-05 2013-07-24 Hera Pharmaceuticals Inc Expression of antibody or a fragment thereof in lactobacillus
CN101985052B (zh) 2010-08-31 2013-11-06 中国人民解放军第二军医大学 自动捕获内皮祖细胞促进血管化的皮肤替代物及其构建方法
ES2702490T3 (es) 2011-05-03 2019-03-01 Dupont Nutrition Biosci Aps Bacterias probióticas para el tratamiento tópico de trastornos de la piel
RU2766157C2 (ru) 2011-06-01 2022-02-08 Интрексон Актобиотикс Н.В. Система полицистронной экспрессии для бактерий
ES2676707T3 (es) 2011-09-23 2018-07-24 Intrexon Actobiotics Nv Bacterias gram positivas modificadas y usos de las mismas
RU2653757C2 (ru) 2011-09-23 2018-05-14 Интрексон Актобиотикс Н.В. Модифицированные грамположительные бактерии и их применение
GB201206599D0 (en) * 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
US20160331809A1 (en) * 2013-03-15 2016-11-17 Juventas Therapeutics, Inc. The use of sdf-1 to mitigate scar formation
WO2014146202A1 (en) * 2013-03-18 2014-09-25 London Health Sciences Centre Research Inc. Bacteria for the prevention, treatment and diagnosis of breast cancer
PL3030232T3 (pl) * 2013-04-29 2022-11-07 Medregen, Llc Gojenie ran poprzez autologiczną mobilizację komórek macierzystych
WO2016124239A1 (en) 2015-02-04 2016-08-11 Aurealis Oy Recombinant probiotic bacteria for use in the treatment of a skin dysfunction

Also Published As

Publication number Publication date
CA2971520C (en) 2024-04-09
US20180187202A1 (en) 2018-07-05
CN107208107B (zh) 2021-07-09
AU2015370982B2 (en) 2019-03-21
ES2864373T3 (es) 2021-10-13
CN113403244A (zh) 2021-09-17
KR102297619B1 (ko) 2021-09-02
JP7033109B2 (ja) 2022-03-09
EP3735979A1 (en) 2020-11-11
CA2971520A1 (en) 2016-06-30
EP3237622B1 (en) 2021-02-24
KR102081493B1 (ko) 2020-02-26
AU2019204290B2 (en) 2021-12-16
AU2019204290A1 (en) 2019-07-04
CN107208107A (zh) 2017-09-26
JP6581208B2 (ja) 2019-09-25
JP2020005646A (ja) 2020-01-16
KR20200020994A (ko) 2020-02-26
CN113403244B (zh) 2022-08-19
KR20170097194A (ko) 2017-08-25
US20200299703A1 (en) 2020-09-24
US11473091B2 (en) 2022-10-18
JP2018502600A (ja) 2018-02-01
WO2016102660A1 (en) 2016-06-30
AU2015370982A1 (en) 2017-07-13
US20230093013A1 (en) 2023-03-23
EP3237622A1 (en) 2017-11-01
US10696974B2 (en) 2020-06-30

Similar Documents

Publication Publication Date Title
CN107208107A8 (zh) 伤口愈合的方法
MX2017016819A (es) Composiciones antimicrobianas y sus usos.
EA202090948A1 (ru) Иммуномодуляция
EP4299122A3 (en) Compositions and methods for treating skin and mucous membrane diseases
WO2016210384A3 (en) Bacteria engineered to treat metabolic diseases
MX354047B (es) Cepas/celulas de lactobacillus secadas por aspersion, y el uso de las mismas contra helicobacter pylori.
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
PH12020550169A1 (en) Isothiocyanate containing brassicaceae products and method of preparation thereof
PH12016502003A1 (en) Novel bacteriophage and composition containing same
PH12017500708A1 (en) Probiotic and prebiotic compositions
EP3554521A4 (en) ORAL LACTIC ACID BACTERIA COMPOSITION FOR THE REGULATION OF IMMUNE REACTIONS AND RELATED PROCEDURES
EP3715449A4 (en) NEW LACTIC BACTERIA AND THEIR USE
WO2018231992A3 (en) METHODS OF USING LACTOBACILLUS PLANTARUM STRAINS TO PROTECT ANIMALS AGAINST PATHOGENIC BACTERIAL INFECTION
EP3431580A4 (en) MILKY ACID BACTERIA FOR THE PREPARATION OF SILAGE AND ADDITIVE FOR THE PRODUCTION OF SILAGE
WO2016200614A3 (en) Bacteria engineered to treat diseases associated with hyperammonemia
WO2015109299A3 (en) Bamboo extracts, compositions and uses thereof
EP3875576A4 (en) NEW LACTIC BACTERIA AND THEIR USE
MX2016014144A (es) Composiciones de proteina concentrada y metodos para su elaboracion y uso.
EA201790685A1 (ru) Пробиотические ферментированные кормовые добавки
EP3483281A4 (en) EXTRACELLULAR POLYSACCHARIDE OF LACTIC ACID BACTERIA AND USE THEREOF
WO2015136287A3 (en) Compositions and methods relating to the treatment of diseases
WO2016102420A3 (en) Novel isothiazolamides, processes for their preparation and their use as herbicides and/or plant growth regulators
PH12016502001B1 (en) Novel bacteriophage and composition comprising same
MX370430B (es) Antagonistas muscarínicos y sus combinaciones para el tratamiento de enfermedades de las vías respiratorias en caballos.
EP3185877A4 (en) Process for enhancing the viable counts of lactic acid bacteria and useful compositions thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CI02 Correction of invention patent application

Correction item: Inventor

Correct: Evelina Wigsjo

False: Evelina Wigsjo|Mia Philipson|Russ Stefan

Number: 39-01

Page: The title page

Volume: 33

Correction item: Inventor

Correct: Evelina Wigsjo

Correct: Evelina Wigsjo

False: Evelina Wigsjo|Mia Philipson|Russ Stefan

Number: 39-01

Number: 39-01

Volume: 33

GR01 Patent grant
GR01 Patent grant